Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance)

Donna Niedzwiecki, Wendy L Frankel, Alan P Venook, Xing Ye, Paula N Friedman, Richard M Goldberg, Robert J Mayer, Thomas Anthony Colacchio, Jude Marie Mulligan, Timothy S Davison, Eamonn O'Brien, Peter Kerr, Patrick G Johnston, Richard D Kennedy, D Paul Harkin, Richard L Schilsky, Monica M Bertagnolli, Robert S Warren, Federico Innocenti

Research output: Contribution to journalArticle

21 Citations (Scopus)
176 Downloads (Pure)

Abstract

PURPOSE: Conventional staging methods are inadequate to identify patients with stage II colon cancer (CC) who are at high risk of recurrence after surgery with curative intent. ColDx is a gene expression, microarray-based assay shown to be independently prognostic for recurrence-free interval (RFI) and overall survival in CC. The objective of this study was to further validate ColDx using formalin-fixed, paraffin-embedded specimens collected as part of the Alliance phase III trial, C9581.

PATIENTS AND METHODS: C9581 evaluated edrecolomab versus observation in patients with stage II CC and reported no survival benefit. Under an initial case-cohort sampling design, a randomly selected subcohort (RS) comprised 514 patients from 901 eligible patients with available tissue. Forty-nine additional patients with recurrence events were included in the analysis. Final analysis comprised 393 patients: 360 RS (58 events) and 33 non-RS events. Risk status was determined for each patient by ColDx. The Self-Prentice method was used to test the association between the resulting ColDx risk score and RFI adjusting for standard prognostic variables.

RESULTS: Fifty-five percent of patients (216 of 393) were classified as high risk. After adjustment for prognostic variables that included mismatch repair (MMR) deficiency, ColDx high-risk patients exhibited significantly worse RFI (multivariable hazard ratio, 2.13; 95% CI, 1.3 to 3.5; P < .01). Age and MMR status were marginally significant. RFI at 5 years for patients classified as high risk was 82% (95% CI, 79% to 85%), compared with 91% (95% CI, 89% to 93%) for patients classified as low risk.

CONCLUSION: ColDx is associated with RFI in the C9581 subsample in the presence of other prognostic factors, including MMR deficiency. ColDx could be incorporated with the traditional clinical markers of risk to refine patient prognosis.

Original languageEnglish
Number of pages10
JournalJournal of Clinical Oncology
Early online date18 Jul 2016
DOIs
Publication statusEarly online date - 18 Jul 2016

Fingerprint Dive into the research topics of 'Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance)'. Together they form a unique fingerprint.

  • Cite this

    Niedzwiecki, D., Frankel, W. L., Venook, A. P., Ye, X., Friedman, P. N., Goldberg, R. M., Mayer, R. J., Colacchio, T. A., Mulligan, J. M., Davison, T. S., O'Brien, E., Kerr, P., Johnston, P. G., Kennedy, R. D., Harkin, D. P., Schilsky, R. L., Bertagnolli, M. M., Warren, R. S., & Innocenti, F. (2016). Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance). Journal of Clinical Oncology. https://doi.org/10.1200/JCO.2015.65.4699